There are many immunogenic characteristics for cervical cancer, such as tumor antigens induced by HPV, high TMB (tumor mutational burden), infiltration of immune cells (particularly CD8+ lymphocytes), and multiple checkpoint control targets, which support the feasibility of immunotherapy intervention (13, 14). This evidence concerns the gene CD8A and cervical carcinoma.